Peptides Reference Library

They are easier than you think

Started in the last century.

A GLP-1 receptor agonist that mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and support blood-sugar regulation. Status: FDA-approved (Ozempic, Wegovy) for type 2 diabetes and obesity.

A dual GLP-1/GIP receptor agonist studied for blood-sugar regulation and appetite. Status: FDA-approved (Mounjaro, Zepbound) for type 2 diabetes and obesity.

An investigational triple-receptor agonist (GLP-1/GIP/glucagon) being studied in Phase 3 trials for weight management. Status: Investigational — not FDA-approved. It cannot currently be legally prescribed, sold as a medicine, or compounded. Products sold online as "retatrutide" are unapproved and unverified.

A modified fragment of human growth hormone studied in research settings for its proposed effect on fat metabolism. Status: Research use only — not FDA-approved for weight loss or any human use.

A long-acting amylin analog studied — including in combination with GLP-1 agonists — for appetite regulation. Status: Investigational — not FDA-approved as a standalone product.

A GHRH analog studied in research for its effect on growth-hormone release. Status: Research use only — not FDA-approved.

Ipamorelin is a growth-hormone secretagogue studied in research. Not FDA-approved. Educational use only.

A synthetic GHRH analog. It is FDA-approved under the brand Egrifta for one specific condition — HIV-associated lipodystrophy — and is not approved for general weight loss, body composition, or anti-aging use.

A GHRH analog historically used to assess growth-hormone function. Status: Not currently marketed as an FDA-approved product in the U.S.; any availability is through compounding and depends on current regulations. Discuss legality with a licensed clinician or pharmacist.

A growth-hormone-releasing peptide studied in research. Status: Research use only — not FDA-approved.

A long-acting synthetic analog of insulin-like growth factor-1 studied in research. Status: Research use only — not FDA-approved. Banned by WADA for athletes.

A protein studied in research for its interaction with myostatin and muscle regulation. Status: Research use only — not FDA-approved; long-term human safety data is lacking.

A synthetic peptide derived from a protein found in gastric juice. In animal and preclinical research it has been studied for possible roles in tissue repair and inflammation; human data is limited. Status: Research use only — not approved for human use. Banned by WADA (2022). Note: its regulatory category in the U.S. has shifted more than once and may change again.

A mitochondria-derived peptide studied in research for its role in cellular energy regulation. Status: Research use only — not FDA-approved.

A thymus-derived peptide studied as an immune modulator. Status: Approved in some countries for chronic hepatitis B and C; not FDA-approved in the U.S.

A peptide studied in research for its interaction with mitochondrial membranes. Status: Investigational — not FDA-approved.

A coenzyme (not a peptide) central to cellular energy and DNA repair, sold as supplements and IV preparations. Status: Not an FDA-approved drug for the longevity or energy uses often claimed for it.

A naturally occurring antimicrobial peptide studied in laboratory research for its role in innate immunity and wound healing. Status: Research use only — not FDA-approved for human use.

An antioxidant tripeptide (glutamine, cysteine, glycine) sold as a supplement and IV preparation. Status: Sold as a dietary supplement; not an FDA-approved drug for detoxification, immune, or anti-aging claims.